A Phase 1 interventional study of Idelalisib in Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma and Follicular Lymphoma, sponsored by Gilead Sciences. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 23rd largest by enrollment, is one of 4 that started in 2014, is one of 3 in phase 1, and was the 18th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 33rd largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2014, is one of 10 in phase 1, and was the 30th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the 28-day safety and tolerability, and to determine the pharmacokinetics (PK) of idelalisib in Japanese participants with relapsed or refractory indolent B-cell non-Hodgkin lymphomas (iNHL) or chronic lymphocytic leukemia (CLL).
Key Inclusion Criteria:
Key Exclusion Criteria:
History of a nonlymphoid malignancy with the following exceptions:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with iNHL or CLL will receive idelalisib until the earliest of the following: unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anticancer or experimental therapy, investigator discretion, or idelalisib discontinuation.
Drug: Idelalisib
150 mg tablet(s) administered orally twice daily
Also known as: Zydelig®, GS-1101, CAL-101
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days of Idelalisib Exposure
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
Time frame: First dose date up to 28 days
Percentage of Participants Experiencing TEAEs Related to Idelalisib Within 28 Days of Idelalisib Exposure
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
Time frame: First dose date up to 28 days
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Within 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment-emergent.The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.
Time frame: First dose date up to 28 days
Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Within 28 Days of Idelalisib Exposure
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
Time frame: First dose date up to 28 days
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 1
Lower limit of quantitation was 5 ng/mL for idelalisib and metabolite GS-563117 both.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose on Day 1
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 8
Time frame: Predose and 1.5 hours postdose on Day 8
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 15
Time frame: Predose and 1.5 hours postdose on Day 15
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 22
Time frame: Predose and 1.5 hours postdose on Day 22
Plasma Concentration of Idelalisib and Its Major Metabolite GS-563117 on Day 29
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose on Day 29
Percentage of Participants Experiencing TEAEs and SAEs Beyond 28 Days of Idelalisib Exposure
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
Time frame: First dose date up to 30 days after last dose (up to approximately 3 years)
Percentage of Participants Experiencing TEAEs Related to Idelalisib Beyond 28 Days of Idelalisib Exposure
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
Time frame: First dose date up to 30 days after last dose (up to approximately 3 years)
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Beyond 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per CTCAE, Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.
Time frame: First dose date up to 30 days after last dose (up to approximately 3 years)
Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Beyond 28 Days of Idelalisib Exposure
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
Time frame: First dose date up to 30 days after last dose (up to approximately 3 years)
Participants were enrolled at study sites in Japan. The first participant was screened on 01 October 2014. The last study visit occurred on 17 October 2017.
| Milestone | Idelalisib |
|---|---|
| Started | 6 |
| Completed | 0 |
| Not completed | 6 |
| Withdrew: Investigator's discretion | 1 |
| Withdrew: Progressive disease | 2 |
| Withdrew: Unable to tolerate rechallenge with idelalisib | 1 |
| Withdrew: Initiated another anti-cancer or experimental therapy | 2 |
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
| percentage of participants | Idelalisib |
|---|---|
| TEAEs | 66.7 |
| SAEs | 16.7 |
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
| percentage of participants | Idelalisib |
|---|---|
| Percentage of Participants Experiencing TEAEs Related to Idelalisib Within 28 Days of Idelalisib Exposure | 0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment-emergent.The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.
| percentage of participants | Idelalisib |
|---|---|
| Leukocytosis (Grade 1) | 0 |
| Leukocytosis (Grade 2) | 0 |
| Leukocytosis (Grade 3) | 16.7 |
| Leukocytosis (Grade 4) | 0 |
| White blood cell decreased (Grade 1) | 16.7 |
| White blood cell decreased (Grade 2) | 0 |
| White blood cell decreased (Grade 3) | 16.7 |
| White blood cell decreased (Grade 4) | 0 |
| Neutrophil count decreased (Grade 1) | 16.7 |
| Neutrophil count decreased (Grade 2) | 16.7 |
| Neutrophil count decreased (Grade 3) | 0 |
| Neutrophil count decreased (Grade 4) | 0 |
| Hypocalcemia (Grade 1) | 0 |
| Hypocalcemia (Grade 2) | 16.7 |
| Hypocalcemia (Grade 3) | 0 |
| Hypocalcemia (Grade 4) | 0 |
| Cholesterol high (Grade 1) | 33.3 |
| Cholesterol high (Grade 2) | 0 |
| Cholesterol high (Grade 3) | 0 |
| Cholesterol high (Grade 4) | 0 |
| Creatinine increased (Grade 1) | 16.7 |
| Creatinine increased (Grade 2) | 0 |
| Creatinine increased (Grade 3) | 0 |
| Creatinine increased (Grade 4) | 0 |
| Chronic Kidney Disease (Grade 1) | 0 |
| Chronic Kidney Disease (Grade 2) | 33.3 |
| Chronic Kidney Disease (Grade 3) | 0 |
| Chronic Kidney Disease (Grade 4) | 0 |
| Hypertriglyceridemia (Grade 1) | 33.3 |
| Hypertriglyceridemia (Grade 2) | 16.7 |
| Hypertriglyceridemia (Grade 3) | 0 |
| Hypertriglyceridemia (Grade 4) | 0 |
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
| percentage of participants | Idelalisib |
|---|---|
| Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Within 28 Days of Idelalisib Exposure | 0 |
Lower limit of quantitation was 5 ng/mL for idelalisib and metabolite GS-563117 both.
| ng/mL | Idelalisib |
|---|---|
| Idelalisib: Predose | NA ± NA |
| Idelalisib: 0.5 hour | 188.4 ± 322.97 |
| Idelalisib: 1 hour | 763.9 ± 1141.85 |
| Idelalisib: 1.5 hour | 1454.0 ± 1255.23 |
| Idelalisib: 2 hour | 2097.4 ± 1483.25 |
| Idelalisib: 3 hour | 2226.5 ± 1231.66 |
| Idelalisib: 4 hour | 2042.3 ± 1048.57 |
| Idelalisib: 6 hour | 1215.0 ± 797.50 |
| Idelalisib: 8 hour | 718.5 ± 532.06 |
| Idelalisib: 12 hour | 291.4 ± 247.66 |
| GS-563117: Predose | NA ± NA |
| GS-563117: 0.5 hour | 6.38 ± 7.095 |
| GS-563117: 1 hour | 134.92 ± 153.644 |
| GS-563117: 1.5 hour | 478.75 ± 507.114 |
| GS-563117: 2 hour | 1005.12 ± 781.188 |
| GS-563117: 3 hour | 2011.00 ± 1206.687 |
| GS-563117: 4 hour | 2121.00 ± 1352.570 |
| GS-563117: 6 hour | 2288.33 ± 1358.446 |
| GS-563117: 8 hour | 2195.00 ± 1494.054 |
| GS-563117: 12 hour | 1677.83 ± 1307.384 |
| ng/mL | Idelalisib |
|---|---|
| Idelalisib: Predose | 463.2 ± 220.75 |
| Idelalisib: 1.5 hour | 2138.5 ± 759.23 |
| GS-563117: Predose | 2703.33 ± 1866.555 |
| GS-563117: 1.5 hour | 3040.00 ± 1736.237 |
| ng/mL | Idelalisib |
|---|---|
| Idelalisib: Predose | 459.3 ± 203.64 |
| Idelalisib: 1.5 hour | 2648.3 ± 1601.70 |
| GS-563117: Predose | 3326.67 ± 2655.234 |
| GS-563117: 1.5 hour | 3636.67 ± 2547.883 |
| ng/mL | Idelalisib |
|---|---|
| Idelalisib: Predose | 358.7 ± 237.86 |
| Idelalisib: 1.5 hour | 2155.0 ± 782.73 |
| GS-563117: Predose | 2318.33 ± 1070.111 |
| GS-563117: 1.5 hour | 2828.33 ± 1749.153 |
| ng/mL | Idelalisib |
|---|---|
| Idelalisib: Predose | 501.2 ± 329.02 |
| Idelalisib: 0.5 hour | 666.8 ± 454.58 |
| Idelalisib: 1 hour | 1107.8 ± 891.69 |
| Idelalisib: 1.5 hour | 1523.3 ± 990.84 |
| Idelalisib: 2 hour | 1940.0 ± 1028.47 |
| Idelalisib: 3 hour | 2313.3 ± 644.13 |
| Idelalisib: 4 hour | 1843.8 ± 701.36 |
| Idelalisib: 6 hour | 1141.2 ± 509.70 |
| Idelalisib: 8 hour | 707.2 ± 340.26 |
| Idelalisib: 12 hour | 403.0 ± 315.41 |
| GS-563117: Predose Day 29 | 3075.00 ± 2546.698 |
| GS-563117: 0.5 hour | 2913.33 ± 2855.182 |
| GS-563117: 1 hour | 2833.33 ± 2535.387 |
| GS-563117: 1.5 hour | 2930.00 ± 2585.660 |
| GS-563117: 2 hour | 3185.00 ± 2799.691 |
| GS-563117: 3 hour | 3781.67 ± 3058.283 |
| GS-563117: 4 hour | 3893.33 ± 2996.309 |
| GS-563117: 6 hour | 3653.33 ± 2900.232 |
| GS-563117: 8 hour | 3428.33 ± 2987.376 |
| GS-563117: 12 hour | 2871.67 ± 3309.601 |
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
| percentage of participants | Idelalisib |
|---|---|
| TEAEs | 100.0 |
| SAEs | 83.3 |
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
| percentage of participants | Idelalisib |
|---|---|
| Percentage of Participants Experiencing TEAEs Related to Idelalisib Beyond 28 Days of Idelalisib Exposure | 83.3 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per CTCAE, Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.
| percentage of participants | Idelalisib |
|---|---|
| Anemia (Grade 1) | 0 |
| Anemia (Grade 2) | 16.7 |
| Anemia (Grade 3) | 0 |
| Anemia (Grade 4) | 0 |
| Leukocytosis (Grade 1) | 0 |
| Leukocytosis (Grade 2) | 0 |
| Leukocytosis (Grade 3) | 16.7 |
| Leukocytosis (Grade 4) | 0 |
| White blood cell decreased (Grade 1) | 50.0 |
| White blood cell decreased (Grade 2) | 0 |
| White blood cell decreased (Grade 3) | 16.7 |
| White blood cell decreased (Grade 4) | 0 |
| Lymphocyte count decreased (Grade 1) | 0 |
| Lymphocyte count decreased (Grade 2) | 16.7 |
| Lymphocyte count decreased (Grade 3) | 16.7 |
| Lymphocyte count decreased (Grade 4) | 0 |
| Neutrophil count decreased (Grade 1) | 33.3 |
| Neutrophil count decreased (Grade 2) | 16.7 |
| Neutrophil count decreased (Grade 3) | 33.3 |
| Neutrophil count decreased (Grade 4) | 0 |
| Alanine aminotransferase increased (Grade 1) | 33.3 |
| Alanine aminotransferase increased (Grade 2) | 0 |
| Alanine aminotransferase increased (Grade 3) | 0 |
| Alanine aminotransferase increased (Grade 4) | 16.7 |
| Hypoalbuminemia (Grade 1) | 0 |
| Hypoalbuminemia (Grade 2) | 16.7 |
| Hypoalbuminemia (Grade 3) | 0 |
| Hypoalbuminemia (Grade 4) | 0 |
| Hypocalcemia (Grade 1) | 0 |
| Hypocalcemia (Grade 2) | 16.7 |
| Hypocalcemia (Grade 3) | 0 |
| Hypocalcemia (Grade 4) | 0 |
| Alkaline phosphatase increased (Grade 1) | 16.7 |
| Alkaline phosphatase increased (Grade 2) | 0 |
| Alkaline phosphatase increased (Grade 3) | 0 |
| Alkaline phosphatase increased (Grade 4) | 0 |
| Aspartate aminotransferase increased (Grade 1) | 33.3 |
| Aspartate aminotransferase increased (Grade 2) | 0 |
| Aspartate aminotransferase increased (Grade 3) | 16.7 |
| Aspartate aminotransferase increased (Grade 4) | 0 |
| Blood bilirubin increased (Grade 1) | 16.7 |
| Blood bilirubin increased (Grade 2) | 0 |
| Blood bilirubin increased (Grade 3) | 0 |
| Blood bilirubin increased (Grade 4) | 0 |
| Cholesterol high (Grade 1) | 16.7 |
| Cholesterol high (Grade 2) | 16.7 |
| Cholesterol high (Grade 3) | 0 |
| Cholesterol high (Grade 4) | 0 |
| Creatinine increased (Grade 1) | 50.0 |
| Creatinine increased (Grade 2) | 16.7 |
| Creatinine increased (Grade 3) | 0 |
| Creatinine increased (Grade 4) | 0 |
| Chronic Kidney Disease (Grade 1) | 0 |
| Chronic Kidney Disease (Grade 2) | 50.0 |
| Chronic Kidney Disease (Grade 3) | 16.7 |
| Chronic Kidney Disease (Grade 4) | 0 |
| Gamma Glutamyl Transferase increased (Grade 1) | 50.0 |
| Gamma Glutamyl Transferase increased (Grade 2) | 16.7 |
| Gamma Glutamyl Transferase increased (Grade 3) | 0 |
| Gamma Glutamyl Transferase increased (Grade 4) | 0 |
| Hyperglycemia (Grade 1) | 50.0 |
| Hyperglycemia (Grade 2) | 0 |
| Hyperglycemia (Grade 3) | 16.7 |
| Hyperglycemia (Grade 4) | 0 |
| Hypophosphatemia (Grade 1) | 0 |
| Hypophosphatemia (Grade 2) | 16.7 |
| Hypophosphatemia (Grade 3) | 33.3 |
| Hypophosphatemia (Grade 4) | 0 |
| Hypokalemia (Grade 1) | 0 |
| Hypokalemia (Grade 2) | 0 |
| Hypokalemia (Grade 3) | 16.7 |
| Hypokalemia (Grade 4) | 16.7 |
| Hyponatremia (Grade 1) | 33.3 |
| Hyponatremia (Grade 2) | 0 |
| Hyponatremia (Grade 3) | 0 |
| Hyponatremia (Grade 4) | 0 |
| Hypertriglyceridemia (Grade 1) | 33.3 |
| Hypertriglyceridemia (Grade 2) | 0 |
| Hypertriglyceridemia (Grade 3) | 33.3 |
| Hypertriglyceridemia (Grade 4) | 0 |
| Hyperuricemia (Grade 1) | 33.3 |
| Hyperuricemia (Grade 2) | 0 |
| Hyperuricemia (Grade 3) | 0 |
| Hyperuricemia (Grade 4) | 0 |
An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as 1 or both of the following: 1) Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; and/or 2) Any AEs leading to premature discontinuation of study drug.
| percentage of participants | Idelalisib |
|---|---|
| Percentage of Participants Who Permanently Discontinued Idelalisib Due to a TEAE Beyond 28 Days of Idelalisib Exposure | 16.7 |
Collected over First dose date up to approximately 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib | 0/6 (0%) | 5/6 (83.3%) | 6/6 (100%) |
| Event | Idelalisib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 3/6 |
| PyrexiaGeneral disorders | 1/6 |
| InfectionInfections and infestations | 1/6 |
| PneumoniaInfections and infestations | 1/6 |
| Transaminases increasedInvestigations | 1/6 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 |
| Event | Idelalisib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 5/6 |
| GastritisGastrointestinal disorders | 3/6 |
| PyrexiaGeneral disorders | 3/6 |
| InsomniaPsychiatric disorders | 3/6 |
| NauseaGastrointestinal disorders | 2/6 |
| Herpes simplexInfections and infestations | 2/6 |
| Upper respiratory tract infectionInfections and infestations | 2/6 |
| Transaminases increasedInvestigations | 2/6 |
| Weight decreasedInvestigations | 2/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/6 |
The Full Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(years) | Idelalisib |
|---|---|
| Mean | 62.3 ± 10.71 |
| Sex: Female, Male(Participants) | Idelalisib |
|---|---|
| Female | 0 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | Idelalisib |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Idelalisib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Oct 2014 to primary completion in Dec 2014, 2 months.
Results were first posted in Mar 2021, 6 years 2 months after primary completion.
Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 2 months is below that.
Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →